Â鶹Æƽâ°æ est heureux d\u2019annoncer le d\u00e9but d\u2019une collaboration avec le groupe du Professeur Patrice Andr\u00e9 (Inserm U1111, Lyon, France) pour \u00e9tudier de fa\u00e7on approfondie la fa\u00e7on dont les agonistes de FXR inhibent le cycle de r\u00e9plication du virus de l\u2019h\u00e9patite B. En plus d\u2019identifier de nouvelles opportunit\u00e9s de traitement anti-VHB cette collaboration va renforcer la compr\u00e9hension du mode d\u2019action de EYP001, mol\u00e9cule phare d\u2019ENYO. EYP001 a la capacit\u00e9 de moduler de fa\u00e7on tr\u00e8s s\u00e9lective l\u2019activit\u00e9 de FXR ce qui permet la r\u00e9duction du r\u00e9servoir de cccDNA du VHB, bloque sa transcription et l\u2019expression d\u00e9l\u00e9t\u00e8re des prot\u00e9ines virales. L’\u00e9tude de phase 1 \u00e0 dose unique a d\u00e9j\u00e0 \u00e9t\u00e9 r\u00e9alis\u00e9e, et celle \u00e0 dose multiple ascendante vient d’\u00eatre initi\u00e9e sur des sujets sains. Elle devrait se terminer au 1er Trimestre 2017.<\/p>\n","protected":false},"excerpt":{"rendered":"
Â鶹Æƽâ°æ est heureux d\u2019annoncer le d\u00e9but d\u2019une collaboration avec le groupe du Professeur Patrice Andr\u00e9 (Inserm U1111, Lyon, France) pour \u00e9tudier de fa\u00e7on approfondie la fa\u00e7on dont les agonistes de FXR inhibent le cycle de r\u00e9plication du virus de l\u2019h\u00e9patite B. En plus d\u2019identifier de nouvelles opportunit\u00e9s de traitement anti-VHB cette collaboration va renforcer la compr\u00e9hension du mode d\u2019action de EYP001, mol\u00e9cule phare d\u2019ENYO. EYP001 a la capacit\u00e9 de moduler de fa\u00e7on tr\u00e8s s\u00e9lective l\u2019activit\u00e9 de FXR ce qui permet la r\u00e9duction du r\u00e9servoir de cccDNA du VHB,<\/p>\n
Lire la suite »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-1527","post","type-post","status-publish","format-standard","hentry","category-latest-news-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"Br\u00e8ves<\/a>","rttpg_excerpt":"Â鶹Æƽâ°æ est heureux d\u2019annoncer le d\u00e9but d\u2019une collaboration avec le groupe du Professeur Patrice Andr\u00e9 (Inserm U1111, Lyon, France) pour \u00e9tudier de fa\u00e7on approfondie la fa\u00e7on dont les agonistes de FXR inhibent le cycle de r\u00e9plication du virus de l\u2019h\u00e9patite B. En plus d\u2019identifier de nouvelles opportunit\u00e9s de traitement anti-VHB cette collaboration va renforcer…","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=1527"}],"version-history":[{"count":2,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1527\/revisions"}],"predecessor-version":[{"id":1534,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1527\/revisions\/1534"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=1527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=1527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=1527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}